Certara (CERT) AI Stock Analysis

Certara

(BMV:CERT)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Software momentumSoftware is becoming a larger portion of Certara’s business while bookings continue to grow, supporting a more recurring and scalable revenue mix. This shift can improve customer retention, operating leverage, and visibility as adoption of drug-development platforms expands.

Negative Factors

Services weaknessWeak services revenue and bookings create a meaningful drag because services remain a large part of Certara’s business. The ongoing go-to-market reorganization adds execution risk, and recovery depends on converting the pipeline into revenue without further disruption.

Certara (CERT) vs. SPDR S&P 500 ETF (SPY)

Market Cap: MXN 1.68B
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -24.9
Beta (1Y): 0.03
Revenue Growth: 0.66%
EPS Growth: -134.07%
Country: Mexico
Employees: 1,546
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Healthcare Information Services

Certara Business Overview & Revenue Model

Company Description

Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery and preclinical research to clinical trials, regulatory sub...

Certara Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:-21.12%|Next Earnings Date:Nov 04, 2026

Earnings Call SentimentNeutral

The call presented a balanced picture: clear, measurable momentum in software, AI integration and product/scientific leadership (strong bookings growth in software, pipeline expansion, cloud wins, regulatory engagement and scientific publications), alongside near-term financial and operational headwinds (service revenue declines, modest overall revenue growth, margin impact from divestiture-related stranded costs, and a GAAP net loss). Management has taken decisive operational actions (RIF, product reprioritization, new CCO, $13M run-rate savings) and is bullish on mid-term growth, but execution risk remains in converting a larger services pipeline and realizing cost savings. On balance the results are cautiously constructive but not yet a decisive turnaround in overall financial performance.

Positive Updates

Modest Top-Line Growth with Software Momentum

Total revenue for Q2 2026 was $93.3M, up 1% year-over-year. Software revenue grew 4% to $48.8M and now represents 53% of the business (versus 40% two years ago). Software bookings for the quarter increased 9% to $50.7M and trailing 12-month software bookings rose 8% to $196.4M.

Negative Updates

Services Revenue and Bookings Decline

Services revenue declined 3% YoY in Q2 to $44.5M; services bookings fell 6% YoY to $47.6M and trailing 12-month services bookings declined 1% to $209M. Management noted services bookings lagged in the quarter and require go-to-market changes.

Company Guidance

Certara reaffirmed full‑year 2026 revenue guidance of 0%–4% growth, which management says equates to $367M–$382M on a continuing‑operations basis, with software expected to be at or above the high end of that range and services at or below the low end; full‑year adjusted EBITDA margin is guided to 29%–31% (revised from 30%–32%), adjusted diluted EPS from continuing operations is $0.31–$0.36, fully diluted shares 155M–157M and an effective tax rate of ~30%. The company is targeting roughly $13M of run‑rate cost savings (after a RIF affecting ~5% of employees), finished Q2 with $184.1M cash, $294M term‑loan borrowings and $100M revolver availability, completed a $100M repurchase program (Q2 repurchases $17.4M) and has a new $50M buyback authorization, and noted the May divestiture of the regulatory/medical‑writing business (which contributed $19.2M revenue and ~$7.5M adjusted EBITDA through May and roughly $17M adjusted EBITDA in 2025) as the primary driver of the change in margin guidance.

Certara Risk Analysis

Certara disclosed 43 risk factors in its most recent earnings report. Certara reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Certara Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

MX:CERT against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OPRX	66Neutral	$175.55M	38.26	3.60%	―	-5.82%	―
SOPH	59Neutral	$649.53M	-6.63	-136.71%	―	23.65%	-4.80%
TEM	56Neutral	$13.16B	-50.50	-54.70%	―	50.43%	-21.05%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
DH	47Neutral	$162.22M	-0.70	-78.52%	―	-4.99%	39.52%

* Healthcare Sector Average

Performance Comparison

MX:CERT and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
MX:CERT	Certara, Inc.	173.28	-46.40	-21.12%
OPRX	Optimizerx Corporation	9.32	-9.46	-50.37%
SOPH	Sophia Genetics Sa	7.63	2.95	63.03%
DH	Definitive Healthcare Corp. Class A	1.12	-1.66	-59.71%
BFRG	BullFrog AI Holdings, Inc.	0.49	-0.60	-55.32%
TEM	Tempus AI, Inc. Class A	72.22	-12.27	-14.52%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Certara AI Stock Analysis